Avid Bioservices, Inc. (CDMO)

NASDAQ: CDMO · IEX Real-Time Price · USD
15.61
-0.12 (-0.76%)
Jun 24, 2022 4:00 PM EDT - Market closed
-0.76%
Market Cap 963.83M
Revenue (ttm) 115.98M
Net Income (ttm) 9.78M
Shares Out 61.74M
EPS (ttm) 0.16
PE Ratio 100.71
Forward PE 34.01
Dividend n/a
Ex-Dividend Date n/a
Volume 791,151
Open 15.91
Previous Close 15.73
Day's Range 15.12 - 16.04
52-Week Range 11.30 - 34.51
Beta 2.32
Analysts Buy
Price Target 30.60 (+96.0%)
Earnings Date Jun 29, 2022

About CDMO

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides var... [Read more...]

Industry Biotechnology
Founded 1981
CEO Nicholas Green
Employees 252
Stock Exchange NASDAQ
Ticker Symbol CDMO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CDMO stock is "Buy." The 12-month stock price forecast is 30.6, which is an increase of 96.03% from the latest price.

Price Target
$30.6
(96.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on J...

TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives ...

Avid Bioservices, Inc. and CRB highlight efforts that enabled opening of first phase of new viral vector facility in ...

53,000-square-foot facility addresses unique demands of commercial-scale viral vector production COSTA MESA, Calif. , June 16, 2022 /PRNewswire/ -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated cont...

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector D...

AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility

Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives...

Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives...

Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know

Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.

Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know

Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility

Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processing Suite in Coming Month Milestone Marks Completion of First Ph...

Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

Other symbols: GILDREGN

Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?

Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.

Avid Bioservices (CDMO) Loses 24.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Avid Bioservices (CDMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street anal...

Avid Bioservices (CDMO) Tops Q2 Earnings and Revenue Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 400% and 4.44%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices: Q2 Earnings Insights

Avid Bioservices (NASDAQ:CDMO) reported its Q2 earnings results on Tuesday, December 7, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Earnings Preview: Avid Bioservices

Avid Bioservices (NASDAQ:CDMO) is set to give its latest quarterly earnings report on Tuesday, 2021-12-07. Here's what investors need to know before the announcement.

7 A-Rated Biotechs to Buy for the Long Run

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Avid Bioservices (CDMO) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avid Bioservices Appoints Elie G. Hanania, Ph.D.

Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth Biotechnologies ...

Will The Rally In Avid Bioservices Stock Continue After 48% Rise In A Month?

The stock price of Avid Bioservices, a contract development and manufacturing company for biopharmaceutical products, has surged 48% in a month (twenty-one trading days), while it is up a solid 19% in a...

Why Avid Bioservices Stock Surged 14% Today

The stock will be part of a well-known index.

Avid Bioservices to Join S&P SmallCap 600 Index

TUSTIN, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives ...

Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market

Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti...